S Takasugi Shinsaku, Koyanskaya of Dark, Florence Nightingale, Altria Pendragon (Archer), Ashiya Douman, Enkidu, Leonardo da Vinci (Rider), Senji Muramasa, Super Orion, Galatea, Leonardo da Vinci ...

In its first quarter 2025 investor letter, Andvari Associates emphasized stocks such as Altria Group, Inc. (NYSE:MO). Altria Group, Inc. (NYSE:MO) is a US-based smokeable and oral tobacco products ...

If Altria keeps its 61% payout ratio, dividends could reach $3.78 per share, yielding 5.6% at a $68 stock price. Though lower than its current 7.1% yield, it may still appeal to income investors ...

Altria (MO) ended the recent trading session at $56.71, demonstrating a -1.63% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.16%.

As markets tumble, there's but a handful of stocks that are posting green candles, and one of them is Altria (NYSE:MO). The tobacco and smoking products manufacturer is a perfect example of a ...

Altria and Philip Morris have differentiated themselves from each other considerably since splitting into two companies. Philip Morris now makes 40% of its revenue from next-gen, smoke-free ...

Tobacco giant Altria Group has stopped selling its NJOY Ace e-cigarettes, after the U.S. International Trade Commission sided with rival Juul Labs in a patent dispute. Consumers can still buy them ...

Altria’s dividend pedigree is impressive, with decades of annual dividend growth under its belt. This stock’s dividend yield is not just superior to most other dividend-paying stocks’ yields ...

Behold, the Lion King. No, not that one. This version of Altria Pendragon manifested in the Lancer class and comes with charged and regular versions of the lance Rhongomyniad, several hand parts ...

In this article, we are going to take a look at where Altria Group, Inc. (NYSE:MO) stands against other stocks that Jim Cramer discusses. On Tuesday, April 1 st, the host of Mad Money opened the ...

Investing.com -- Shares of Altria Group (NYSE:MO) dropped 4.5% following a U.S. Supreme Court decision largely in favor of the Food and Drug Administration’s rejection of applications for ...